- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04157192
Brain Connectome for Acupuncture-treated Migraine Patients (ACU-BRAIN)
Brain Connectome for Migraine Patients Treated Via Acupuncture: A Randomized, Controlled Study Under Single-blind Conditions, With a Placebo Group and Magnetic Resonance Imaging (MRI)
Acupuncture has been a means of treating headaches and migraine since 2002 and is now a World Health Organisation-recognized prophylactic treatment for migraine. Brain activation/de-activation via acupuncture modifies the haemodynamic responses in the brain which may impact the sensorial, cognitive and affective dimensions of pain. Randomized studies on patients suffering from aura-free migraine have shown that the painkilling effect of regular acupuncture sessions on the cerebral substratum, compared with simulated sham-type acupuncture, can reduce the frequency of bouts of migraine, number of days with headaches and also their intensity.
Modifications to the white matter (WM) and grey matter (GM) occur after repeated sessions of acupuncture treatment for pain and these are observable via magnetic resonance imaging (MRI). It is a very sensitive technique and often used to detect functional and structural brain changes.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Since 2002, acupuncture has been employed as a method for treating headaches and migraine. It is recognized by the World Health Organisation (WHO), and is now part of the prophylactic treatments for migraine. Brain activations/de-activation via acupuncture lead to a modification of haemodynamic responses in the brain which may impact the sensorial, cognitive and affective dimensions of pain. Randomized studies on patients who suffer from migraine without aura have shown that the painkilling effect of repeated acupuncture sessions on the cerebral substratum, compared with simulated sham-type acupuncture, make it possible to reduce the frequency of bouts of migraine, the number of days of headaches, and the intensity of the bouts.
Following repeated sessions of acupuncture treatment for pain, modifications occur in the white matter (WM) and in the grey matter (GM) and these may be observed by magnetic resonance imaging (MRI) which is a highly sensitive technique and very often used to detect functional brain changes and/or subtle abnormalities.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Marc FREARD, Dr.
- Phone Number: 06.19.42.18.37
- Email: marc.freard@chu-nimes.fr
Study Contact Backup
- Name: Fabricio PEREIRA, Dr.
- Phone Number: 07.85.92.64.02
- Email: fabricio.pereira@umontpellier.fr
Study Locations
-
-
-
Nîmes, France
- Recruiting
- Marc FREARD
-
Contact:
- Marc FREARD
- Phone Number: 0619421837
- Email: marc.freard@chu-nimes.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All patients with two to eight bouts of migraine without an aura per month
- All patient aged (≥) 18 to (≤) 60 years old
- All patients who have not had a bout of migraine in the last 24 hours
- All patients who have given free informed consent and have signed the consent form.
- All patients who are affiliated to or beneficiaries of a health insurance scheme
- All patients available for a two-month follow-up
Exclusion Criteria:
- All patients with migraine which is secondary to a neurological, neuropsychiatric, or vascular disorder
- All patients suffering from diabetes
- All patients with a past history of alcohol or drug abuse
- All patients with contraindications for an MRI scan
- All patients on antidepressants or Botox.
- All patients already taking part in Category 1 research involving the human person
- All patients on an exclusion period determined by another study
- All patients placed under judicial protection, guardianship, or supervision
- All patients for whom it is impossible to give the subject clear information
- All patients who are pregnant, about to give birth or breastfeeding
- All patient who have received botulinum toxin in the past year
- All patient who have undergone antidepressant treatment in the last 2 months
- All patient who have started a background migraine treatment for less than 3 months
- All patient who have more than 14 migraine days per month
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Patients receiving real acupuncture treatment
Treatment with needle insertion
|
The patient will be treated for migraine with real acupuncture.
|
Sham Comparator: Patients receiving sham acupuncture treatment
Treatment without needle insertion
|
Sham acupuncture is used as a control in scientific studies to test the efficacy of acupuncture in the treatment of various disorders, in this case, migraine.
In this study, the subjects will not know whether they are getting true acupuncture or not.
In the placebo group, the acupuncture needles will not actually be inserted into the skin.
Placebo needles consisting of a sliding tube and a retractible needle are applied to the acupunture reference point (marked by a pastille stuck on the skin).
The patient should not be able to feel the difference between real acupuncture and sham acupuncture.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Regional homogeneity map in Interventional group patients BEFORE first real acupuncture session.
Time Frame: At the inclusion visit (Vinc) on Day 0 - Start of therapy
|
Regional homogeneity in patients treated via real acupuncture (Interventional group) is computed with functional magnetic resonance imaging
|
At the inclusion visit (Vinc) on Day 0 - Start of therapy
|
Regional homogeneity map in Interventional group patients AFTER first real acupuncture session.
Time Frame: At the inclusion visit (Vinc) on Day 0 - Start of therapy
|
Regional homogeneity in patients treated via real acupuncture (Interventional group) is computed with functional magnetic resonance imaging
|
At the inclusion visit (Vinc) on Day 0 - Start of therapy
|
Regional homogeneity map in Placebo group patients BEFORE first real acupuncture session.
Time Frame: At the inclusion visit (Vinc) on Day 0 - Start of therapy
|
Regional homogeneity in patients treated via simulated, sham-type acupuncture (Placebo group) is computed with functional magnetic resonance imaging
|
At the inclusion visit (Vinc) on Day 0 - Start of therapy
|
Regional homogeneity map in Placebo group patients AFTER first real acupuncture session.
Time Frame: At the inclusion visit (Vinc) on Day 0 - Start of therapy
|
Regional homogeneity in patients treated via simulated, sham-type acupuncture (Placebo group) is computed with functional magnetic resonance imaging
|
At the inclusion visit (Vinc) on Day 0 - Start of therapy
|
Regional homogeneity map in Interventional group patients BEFORE last real acupuncure session
Time Frame: Sixty days after inclusion in the trial (Day 60) - end of therapy
|
Regional homogeneity in patients treated via acupuncture (Interventional group) is is computed with functional magnetic resonance imaging
|
Sixty days after inclusion in the trial (Day 60) - end of therapy
|
Regional homogeneity map in Interventional group patients AFTER last real acupuncure session
Time Frame: Sixty days after inclusion in the trial (Day 60) - end of therapy
|
Regional homogeneity in patients treated via acupuncture (Interventional group) is computed with functional magnetic resonance imaging
|
Sixty days after inclusion in the trial (Day 60) - end of therapy
|
Regional homogeneity map of Placebo group patients BEFORE last placebo acupuncture session
Time Frame: Sixty days after inclusion in the trial (Day 60) - end of therapy
|
Regional homogeneity in patients treated via simulated, sham-type acupuncture (Placebo group) is computed with functional magnetic resonance imaging
|
Sixty days after inclusion in the trial (Day 60) - end of therapy
|
Regional homogeneity map of Placebo group patients AFTER last placebo acupuncture session
Time Frame: Sixty days after inclusion in the trial (Day 60) - end of therapy
|
Regional homogeneity in patients treated via simulated, sham-type acupuncture (Placebo group) is computed with functional magnetic resonance imaging
|
Sixty days after inclusion in the trial (Day 60) - end of therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean diffusivity of White Matter of Interventional group patients BEFORE first real acupuncture session
Time Frame: At the inclusion visit (Vinc) on Day 0 - start of therapy
|
The mean diffusivity of White Matter of Interventional group patients is computed with diffusion-weighted magnetic resonance imaging
|
At the inclusion visit (Vinc) on Day 0 - start of therapy
|
Mean diffusivity of White Matter of Interventional group patients AFTER first real acupuncture session
Time Frame: At the inclusion visit (Vinc) on Day 0 - start of therapy
|
The mean diffusivity of White Matter of Interventional group patients is computed with diffusion-weighted magnetic resonance imaging
|
At the inclusion visit (Vinc) on Day 0 - start of therapy
|
Mean diffusivity of White Matter of Placebo group patients BEFORE first placebo acupuncture session
Time Frame: At the inclusion visit (Vinc) on Day 0 - start of therapy
|
The mean diffusivity of White Matter of Placebo group patients is computed with diffusion-weighted magnetic resonance imaging
|
At the inclusion visit (Vinc) on Day 0 - start of therapy
|
Mean diffusivity of White Matter of Placebo group patients AFTER first placebo acupuncture session
Time Frame: At the inclusion visit (Vinc) on Day 0 - start of therapy
|
The mean diffusivity of White Matter of Placebo group patients is computed with diffusion-weighted magnetic resonance imaging
|
At the inclusion visit (Vinc) on Day 0 - start of therapy
|
Mean diffusivity of White Matter of Interventional group patients BEFORE last real acupuncture session
Time Frame: 60 days after the initial inclusion visit (Day 60) - end of therapy
|
The mean diffusivity of White Matter in patients treated with real acupuncture (Interventional group) is computed with diffusion-weighted magnetic resonance imaging
|
60 days after the initial inclusion visit (Day 60) - end of therapy
|
Mean diffusivity of White Matter of Interventional group patients AFTER last real acupuncture session
Time Frame: 60 days after the initial inclusion visit (Day 60) - end of therapy
|
The mean diffusivity of White Matter in patients treated with real acupuncture (Interventional group) is computed with diffusion-weighted magnetic resonance imaging
|
60 days after the initial inclusion visit (Day 60) - end of therapy
|
Mean diffusivity of White Matter of Placebo group patients BEFORE last placebo acupuncture session
Time Frame: 60 days after the initial inclusion visit (Day 60) - end of therapy
|
The mean diffusivity of White Matter in patients treated with simulated, sham-type acupuncture (Placebo group) is computed with diffusion-weighted magnetic resonance imaging
|
60 days after the initial inclusion visit (Day 60) - end of therapy
|
Mean diffusivity of White Matter of Placebo group patients AFTER last placebo acupuncture session
Time Frame: 60 days after the initial inclusion visit (Day 60) - end of therapy
|
The mean diffusivity of White Matter in patients treated with simulated, sham-type acupuncture (Placebo group) is computed with diffusion-weighted magnetic resonance imaging
|
60 days after the initial inclusion visit (Day 60) - end of therapy
|
Radial diffusivity of the White Matter in Interventional group patients BEFORE first real acupuncture session
Time Frame: At the inclusion visit (Vinc) on Day 0 - start of therapy
|
Radial diffusivity of the White Matter of Interventional group patients is computed with diffusion-weighted magnetic resonance imaging
|
At the inclusion visit (Vinc) on Day 0 - start of therapy
|
Radial diffusivity of the White Matter in Interventional group patients AFTER first real acupuncture session
Time Frame: At the inclusion visit (Vinc) on Day 0 - start of therapy
|
Radial diffusivity of the White Matter in the Interventional group patients is computed with diffusion-weighted magnetic resonance imaging
|
At the inclusion visit (Vinc) on Day 0 - start of therapy
|
Radial diffusivity of the White Matter in Placebo group patients BEFORE first placebo acupuncture session
Time Frame: At the inclusion visit (Vinc) on Day 0 - start of therapy
|
Radial diffusivity of the White Matter in patients treated with simulated, sham-type acupuncture (Placebo group) is computed with diffusion-weighted magnetic resonance imaging
|
At the inclusion visit (Vinc) on Day 0 - start of therapy
|
Radial diffusivity of the White Matter in Placebo group patients AFTER first placebo acupuncture session
Time Frame: At the inclusion visit (Vinc) on Day 0 - start of therapy
|
Radial diffusivity of the White Matter in patients treated with simulated, sham-type acupuncture (Placebo group) is computed with diffusion-weighted magnetic resonance imaging
|
At the inclusion visit (Vinc) on Day 0 - start of therapy
|
Radial diffusivity of the White Matter in Interventional group patients BEFORE last real acupuncture session
Time Frame: 60 days after the initial inclusion visit (Day 60) - end of therapy
|
Radial diffusivity of the White Matter in patients treated with real acupuncture (Interventional group) is computed with diffusion-weighted magnetic resonance imaging
|
60 days after the initial inclusion visit (Day 60) - end of therapy
|
Radial diffusivity of the White Matter in Placebo group patients AFTER last real acupuncture session
Time Frame: 60 days after the initial inclusion visit (Day 60) - end of therapy
|
Radial diffusivity of the White Matter in patients treated with real acupuncture (Interventional group) is computed with diffusion-weighted magnetic resonance imaging
|
60 days after the initial inclusion visit (Day 60) - end of therapy
|
Radial diffusivity of the White Matter in Interventional group patients BEFORE last placebo acupuncture session
Time Frame: 60 days after the initial inclusion visit (Day 60) - end of therapy
|
Radial diffusivity of the White Matter in patients treated with simulated, sham-type acupuncture (Placebo group) is computed with diffusion-weighted magnetic resonance imaging
|
60 days after the initial inclusion visit (Day 60) - end of therapy
|
Radial diffusivity of the White Matter in Placebo group patients AFTER last placebo acupuncture session
Time Frame: 60 days after the initial inclusion visit (Day 60) - end of therapy
|
Radial diffusivity of the White Matter in patients treated with simulated, sham-type acupuncture (Placebo group) is computed with diffusion-weighted magnetic resonance imaging
|
60 days after the initial inclusion visit (Day 60) - end of therapy
|
Fractional anisotropy of the White Matter in Interventional group patients BEFORE first real acupuncture session
Time Frame: At the inclusion visit (Vinc) on Day 0 - start of therapy
|
Fractional anisotropy of patients treated with real acupuncture (Interventional group) is computed with diffusion-weighted magnetic resonance imaging
|
At the inclusion visit (Vinc) on Day 0 - start of therapy
|
Fractional anisotropy of the White Matter in Interventional group patients AFTER first real acupuncture session
Time Frame: At the inclusion visit (Vinc) on Day 0 - start of therapy
|
Fractional anisotropy of patients treated with real acupuncture (Interventional group) is computed with diffusion-weighted magnetic resonance imaging
|
At the inclusion visit (Vinc) on Day 0 - start of therapy
|
Fractional anisotropy of the White Matter in Placebo group patients BEFORE first placebo acupuncture session
Time Frame: At the inclusion visit (Vinc) on Day 0 - start of therapy
|
Fractional anisotropy in patients treated with simulated, sham-type acupuncture (Placebo group) is computed with diffusion-weighted magnetic resonance imaging
|
At the inclusion visit (Vinc) on Day 0 - start of therapy
|
Fractional anisotropy of the White Matter in Placebo group patients AFTER first placebo acupuncture session
Time Frame: At the inclusion visit (Vinc) on Day 0 - start of therapy
|
Fractional anisotropy in patients treated with simulated, sham-type acupuncture (Placebo group) is computed with diffusion-weighted magnetic resonance imaging
|
At the inclusion visit (Vinc) on Day 0 - start of therapy
|
Fractional anisotropy of the White Matter in Interventional group patients BEFORE last real acupuncture session
Time Frame: 60 days after the initial inclusion visit (Day 60) - end of therapy
|
Fractional anisotropy in patients treated with real acupuncture (Interventional group) is computed with diffusion-weighted magnetic resonance imaging
|
60 days after the initial inclusion visit (Day 60) - end of therapy
|
Fractional anisotropy of the White Matter in Interventional group patients AFTER last real acupuncture session
Time Frame: 60 days after the initial inclusion visit (Day 60) - end of therapy
|
Fractional anisotropy in patients treated with real acupuncture (Interventional group) is computed with diffusion-weighted magnetic resonance imaging
|
60 days after the initial inclusion visit (Day 60) - end of therapy
|
Fractional anisotropy of the White Matter in Placebo group patients BEFORE last placebo acupuncture session
Time Frame: 60 days after the initial inclusion visit (Day 60) - end of therapy
|
Fractional anisotropy in patients treated with simulated, sham-type acupuncture (Placebo group) is computed with diffusion-weighted magnetic resonance imaging
|
60 days after the initial inclusion visit (Day 60) - end of therapy
|
Fractional anisotropy of the White Matter in Placebo group patients AFTER first placebo acupuncture session
Time Frame: 60 days after the initial inclusion visit (Day 60) - end of therapy
|
Fractional anisotropy in patients treated with simulated, sham-type acupuncture (Placebo group) is computed with diffusion-weighted magnetic resonance imaging
|
60 days after the initial inclusion visit (Day 60) - end of therapy
|
Change in number of days with migraine per month - Interventional group BEFORE treatment
Time Frame: At the inclusion visit (Vinc) on Day 0
|
The number of days with migraine per month will be measured according to the days noted on a calendar
|
At the inclusion visit (Vinc) on Day 0
|
Change in number of days with migraine per month - Interventional group AFTER treatment
Time Frame: At the end of the study (on Day 90)
|
The number of days with migraine per month will be measured according to the days noted on a calendar
|
At the end of the study (on Day 90)
|
Change in number of days with migraine per month - Placebo group BEFORE treatment
Time Frame: At the inclusion visit (Vinc) on Day 0
|
The number of days with migraine per month will be measured according to the days noted on a calendar
|
At the inclusion visit (Vinc) on Day 0
|
Change in number of days with migraine per month - Placebo group AFTER treatment
Time Frame: At the end of the study (on Day 90)
|
The number of days with migraine per month will be measured according to the days noted on a calendar
|
At the end of the study (on Day 90)
|
Pain BEFORE treatment in the Interventional group
Time Frame: At the inclusion visit (Vinc) on Day 0
|
The change in pain will be measured according to the Visual Analogue Scale (VAS) described by Huskisson.
The VAS is a simple numerical scale for measuring the intensity of pain.
It is represented in the form of a 100 mm continuous line ranging from "Absence of pain" (0 mm) to "Maximum Imaginable Pain" (100 mm).
The patient slides the cursor to give the intensity of pain that he/she feels.
The amount of pain felt will be reported on the migraine calendar.
|
At the inclusion visit (Vinc) on Day 0
|
Pain AFTER treatment in the Interventional group
Time Frame: At the end of the study (on Day 90)
|
The change in pain will be measured according to the Visual Analogue Scale (VAS) described by Huskisson.
The VAS is a simple numerical scale for measuring the intensity of pain.
It is represented in the form of a 100 mm continuous line ranging from "Absence of pain" (0 mm) to "Maximum Imaginable Pain" (100 mm).
The patient slides the cursor to give the intensity of pain that he/she feels.
The amount of pain felt will be reported on the migraine calendar.
|
At the end of the study (on Day 90)
|
Pain BEFORE treatment in the Placebo group
Time Frame: At the inclusion visit (Vinc) on Day 0
|
The change in pain will be measured according to the Visual Analogue Scale (VAS) described by Huskisson.
The VAS is a simple numerical scale for measuring the intensity of pain.
It is represented in the form of a 100 mm continuous line ranging from "Absence of pain" (0 mm) to "Maximum Imaginable Pain" (100 mm).
The patient slides the cursor to give the intensity of pain that he/she feels.
The amount of pain felt will be reported on the migraine calendar.
|
At the inclusion visit (Vinc) on Day 0
|
Pain AFTER treatment in the Placebo group
Time Frame: At the end of the study (on Day 90)
|
The change in pain will be measured according to the Visual Analogue Scale (VAS) described by Huskisson.
The VAS is a simple numerical scale for measuring the intensity of pain.
It is represented in the form of a 100 mm continuous line ranging from "Absence of pain" (0 mm) to "Maximum Imaginable Pain" (100 mm).
The patient slides the cursor to give the intensity of pain that he/she feels.
The amount of pain felt will be reported on the migraine calendar.
|
At the end of the study (on Day 90)
|
Impact of migraine on the Interventional group patients' Quality of Life (QOL) BEFORE treatment
Time Frame: At the inclusion visit (Vinc) on Day 0
|
The evolution of the impact of migraine on the patient's Quality of Life (QOL) before and after treatment will be measured on a score of 36 to 78 points by means of the Headache Impact Test-6 (HIT-6).
This is a tool used to measure the impact of headaches on the patient's ability to function at work, at school, at home and in social situations.
|
At the inclusion visit (Vinc) on Day 0
|
Impact of migraine on the Interventional group patients' Quality of Life (QOL) AFTER treatment
Time Frame: At the end of the study on Day 90
|
The evolution of the impact of migraine on the patient's Quality of Life (QOL) before and after treatment will be measured on a score of 36 to 78 points by means of the Headache Impact Test-6 (HIT-6).
This is a tool used to measure the impact of headaches on the patient's ability to function at work, at school, at home and in social situations.
|
At the end of the study on Day 90
|
Impact of migraine on the Placebo group patients' Quality of Life (QOL) BEFORE treatment.
Time Frame: At the inclusion visit (Vinc) on Day 0
|
The evolution of the impact of migraine on the patient's Quality of Life (QOL) before and after treatment will be measured on a score of 36 to 78 points by means of the Headache Impact Test-6 (HIT-6).
This is a tool used to measure the impact of headaches on the patient's ability to function at work, at school, at home and in social situations.
|
At the inclusion visit (Vinc) on Day 0
|
Impact of migraine on the Placebo group patients' Quality of Life (QOL) AFTER treatment.
Time Frame: At the end of the study on Day 90
|
The evolution of the impact of migraine on the patient's Quality of Life (QOL) before and after treatment will be measured on a score of 36 to 78 points by means of the Headache Impact Test-6 (HIT-6).
This is a tool used to measure the impact of headaches on the patient's ability to function at work, at school, at home and in social situations.
|
At the end of the study on Day 90
|
Collaborators and Investigators
Investigators
- Study Director: Anissa MEGZARI, Mme., CHU de Nîmes (Nîmes University Hospital)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RCB : 2019-A00588-49
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acupuncture Therapy
-
Shanghai Yueyang Integrated Medicine HospitalNot yet recruitingAnalgesia | Acupuncture Therapy | Perioperative Period | Pneumonectomy
-
University of Sao PauloCompletedAcupuncture Therapy | Electroacupuncture | Thermography
-
Dongzhimen Hospital, BeijingNot yet recruitingHot Flashes | Acupuncture Therapy | Postmenopausal Symptoms | Perimenopausal Disorder
-
Guang'anmen Hospital of China Academy of Chinese...RecruitingHot Flashes | Acupuncture Therapy | Postmenopausal Symptoms | Perimenopausal DisorderChina
-
Mayo ClinicCompleted
-
University of Medicine and Pharmacy at Ho Chi Minh...RecruitingEpilepsy, Drug Resistant | Acupuncture TherapyVietnam
-
Shanghai Yueyang Integrated Medicine HospitalRecruitingAnxiety | Acupuncture Therapy | Thoracoscopic Surgery | Preoperative PeriodChina
-
The First Affiliated Hospital of Hunan University...RecruitingAcupuncture Therapy | Ovarian Reserve | MeridianChina
-
China Medical University HospitalNational Health Research Institutes, TaiwanCompleted
-
Universidade do PortoCompletedQuality of Life | Activities of Daily Living | Acupuncture Therapy | Hemodialysis PatientsPortugal
Clinical Trials on Real acupuncture
-
Universidad de la RepublicaActive, not recruitingMyofascial Pain | Craniofacial PainUruguay
-
Kyung Hee University Hospital at GangdongNational Research Foundation of KoreaUnknownChronic SciaticaKorea, Republic of
-
Kyung Hee University Hospital at GangdongCompleted
-
Federal University of São PauloCompleted
-
Rambam Health Care CampusCompleted
-
Assaf-Harofeh Medical CenterCompletedBack Pain | Anxiety | Neck Pain | Range of MotionIsrael
-
Huazhong University of Science and TechnologyThe University of Hong Kong; Heilongjiang University of Chinese Medicine; Hubei...CompletedPolycystic Ovary SyndromeChina
-
Massachusetts General HospitalUnknown
-
Massachusetts General HospitalRecruitingChronic PainUnited States
-
Memorial Sloan Kettering Cancer CenterGateway for Cancer ResearchRecruitingBreast Cancer | Taxane-Induced Peripheral NeuropathyUnited States